Page 1 - reflections_newsletter_June8_2022

REFLECTIONS dae mia

Dyslipidaemia Global Newsletter #2

TABLE OF CONTENTS Dyslipiad
On behalf of the Scientific Planning Committee, I woDuyldslipi
KEY ARTICLES
like to welcome you back to the second newsletter in our
2021 ACC expert consensus decision pathway on the series where we summarize the latest clinical and real-world
management of ASCVD risk reduction in patients with evidence in the field of dyslipidaemia and reflect on the clinical
persistent hypertriglyceridemia: A report of the American impact of these data on dyslipidaemia management. As
College of Cardiology solution set oversight committee. with the previous installment, we invite you to interact with
Virani SS, et al. J Am Coll Cardiol. 2021 Aug 31;78(9):960-993. this newsletter through links to podcasts, listen to/view short
clinical perspectives from our SPC, and delve into the articles
Coronary atherosclerotic plaque regression: JACC state- through hyperlinks for in-depth study.
of-the-art review. Dawson LP, et al. J Am Coll Cardiol. 2022
Jan 4;79(1):66-82 Prof. Farnier (Chair)

Association between cumulative low-density lipoprotein SCIENTIFIC PLANNING COMMITTEE
cholesterol exposure during young adulthood and middle
age and risk of cardiovascular events. Zhang Y, et al. JAMA Prof. Michel Farnier Prof. Augusto Lavalle
Cardiol. 2021 Dec 1;6(12):1406-1413. (France) Cobo
Prof. Miriam Sandín (Argentina)
Managing atherosclerotic cardiovascular risk in young (Spain) Prof. Lourdes Santos
adults: JACC state-of-the-art review. Stone NJ, et al. J Am (Philippines)
Coll Cardiol. 2022 Mar 1;79(8):819-836.
Prof. Marcin Welnicki
Combination lipid-lowering therapy as first-line strategy in (Poland)
very high-risk patients. Ray KK, et al. Eur Heart J. 2022 Feb
22;43(8):830-833. doi: 10.1093/eurheartj/ehab718.

Adherence to lipid-lowering treatment by single-pill
combination of statin and ezetimibe. Rea F, et al. Adv Ther.
2021;38(10):5270-5285.

Prevalence of statin intolerance: A meta-analysis. Bytyçi
I, et al. Eur Heart J. 2022 Feb 16:ehac015. doi: 10.1093/
eurheartj/ehac015. Online ahead of print.

ADDITIONAL ARTICLES OF INTEREST

2021 ACC expert consensus decision pathway on the management of ASCVD
risk reduction in patients with persistent hypertriglyceridemia: A report of the
American College of Cardiology solution set oversight committee.

Virani SS, et al. J Am Coll Cardiol. 2021 Aug 31;78(9):960-993.

The American College of Cardiology (ACC) has recently provided a broader update to the previous AHA/ACC 2018 guidelines which
highlighted the specific patient groups most likely to benefit from statin therapy for ASCVD risk reduction. These updated guidelines
incorporate results from REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Interventional Trial), which used a
triglyceride risk-based approach by including patients with ASCVD or those with diabetes mellitus plus additional ASCVD risk factors
and elevated triglycerides, and showed that the addition of high-dose icosapent ethyl to statin therapy led to a significant relative and
absolute reduction in the risk of ASCVD events and cardiovascular mortality.

In these new 2021 guidelines, adherence to certain lifestyle interventions, including regular physical activity and avoidance of
tobacco, as well as the use of lipid-lowering medications, are recommended to reduce the risk for ASCVD in patients with persistent
hypertriglyceridaemia.

This provides comprehensive and practical information for clinicians on triglyceride measurement, evaluation, and management of

Learn more at: www.serviercardiomedicalhub.com